Why does the article argue that AstraZeneca should avoid a $400bn mega-merger with Bristol Myers Squibb?

The article argues that AstraZeneca should avoid the $400bn merger because it contradicts CEO Pascal Soriot’s long-standing, patient-centric strategy; would require massive cost-cutting that Soriot has previously viewed as 'anti-patient'; carries significant financial risk due to likely heavy debt from acquiring a $133bn rival; lacks clear strategic justification given AZ’s proven success with internal R&D, smart licensing, and partnerships—especially in China; and faces uncertain regulatory approval, particularly in the US, where combining two leading oncology franchises would raise antitrust concerns.

What is AstraZeneca’s current strategic approach, according to the article, and why is it described as a 'winning formula'?

According to the article, AstraZeneca’s current strategy centers on supplementing its own drug development pipeline with 'smart licensing and partnerships, especially in China', rather than pursuing large-scale acquisitions. This approach is described as a 'proven winner' because it aligns with Soriot’s science-first philosophy—as demonstrated by the successful integration of Alexion into rare disease therapeutics—and has delivered sustained confidence in growth targets, such as the $80bn revenue goal for 2030, even amid late-stage clinical setbacks like the failed heart disease drug, given the strength of its near-term pipeline ('20 high-value readouts due over the next 18 months').

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

Aug 4, 2026

An editorial advises AstraZeneca against a proposed $400bn merger with Bristol Myers Squibb, recommending it stick to its organic growth strategy rather than high-risk financial engineering. Concerns include regulatory hurdles and debt despite the company's strong oncology portfolio.

theguardian

2026-08-02

AstraZeneca Holds Talks with Bristol Myers Squibb on $400 Billion Megadeal, FT Reports

2026-08-03

Wall Street Rallies, Dow Closes at Record on Iran Talks Optimism

2026-08-03

Morning Bid: Much 'To Do' About Yen Intervention

2026-08-04

Business Watch: War doesn’t stop Gulf chemical makers; BMS and AstraZeneca reportedly in merger talks

2026-08-04

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger